How Anthropic is Using Claude to Accelerate Drug Discovery and Development
Anthropic Details Preclinical Progress Across Six Drug Partners and Internal AI Pipelines
Anthropic announced an expanded life-sciences initiative on October 27, 2026, detailing early-stage preclinical results from research partnerships with six drug development organizations alongside its own internal discovery pipelines, according to an update published by anthropic.com. The work covers multiple phases of drug creation, ranging from target identification and molecular design to manufacturing documentation and clinical trial planning.
- The Tech TL;DR:
- Generate Biomedicines utilized Claude Code to engineer a CAR T-cell therapy component that was approximately 70% shorter than standard versions, achieving roughly 10 times more receptors in lab tests.
- Enveda connected manufacturing documentation to Claude, reducing human review time by 89% across 1,061 pages while catching 11 previously identified issues and 7 missed by human reviewers.
- Divergence Labs generated roughly 35,000 antibody designs in about a month, identifying three designs capable of binding IgE and 20 capable of dislodging it.
Claude Helps Design Shorter CAR T-Cell Components
At Generate Biomedicines, Claude Code was used to propose new designs for a specific part of a CAR T-cell therapy component. According to anthropic.com, one resulting design measured about 70% shorter than the standard version. Laboratory tests showed it enabled immune cells to produce roughly 10 times as many receptors, kill tumor cells more efficiently, and remain active for longer periods.
Divergence Labs applied the AI model to food allergy treatments by targeting IgE molecules attached to immune cells. Claude generated approximately 35,000 antibody designs over roughly one month. Early tests yielded three designs capable of binding IgE and 20 capable of dislodging it, with three of the 20 appearing to dislodge IgE more effectively than standard medications.
Lead Optimization and Manufacturing Documentation Workflows
BigHat Biosciences partnered with an Anthropic researcher to optimize two antibody fragments targeting cancer cells and extending drug retention times. Connected to BigHat’s Reccy lab data system, Claude proposed molecular modifications that allowed BigHat to test 1,010 variants over 10 weeks. The optimized leads exhibited binding more than 10 times tighter, increased thermal stability by 18°C in solution, and reduced clumping rates by a factor of 100.
Manufacturing chemists at Enveda integrated their documentation with Claude to manage quality standards and regulatory filings. In trials covering 1,061 pages of records, the model identified all 11 issues flagged by human reviewers plus seven additional errors. This reduced manual review time from over 25 hours to under three hours. Claude drafted initial regulatory filings in four hours, compared to a three-month manual baseline.
Anthropic Partners to Create Biotech Firm and Evaluate Trials
The Column Group collaborated with Anthropic to establish Pleiades, a new biotechnology firm designed to operate multiple complex drug programs using Claude. Its initial evaluation skill has been tested across 45 target-disease pairs. Anthropic also partnered with Bristol Myers Squibb to evaluate early-stage clinical trial plans and estimate success probabilities. A Bristol Myers Squibb executive noted that the model generated initial analyses from single prompts that would otherwise require days to complete.
We use Claude at the clinical trial stage to analyze proprietary data, create a clinical study plan, and weigh the study’s chance of success. From a single prompt, Claude generated a robust initial analysis that helped inform our assessment of different development options, which would otherwise take days to complete. We did all of this while ensuring the security of our highly sensitive data,
said a Bristol Myers Squibb executive.
Anthropic Acquires Mithril Medicine to Treat Muscular Dystrophy
Anthropic expanded its internal efforts by acquiring Mithril Medicine, a single-person entity developing treatments for rare forms of muscular dystrophy. Founder Cody Tranbarger utilized Claude to coordinate logistics and experiments across 11 external laboratories, advancing a potential treatment from concept to positive mouse model results in under 18 months. Anthropic indicated that human clinical trials for these candidates could potentially commence by late 2028, contingent on continued preclinical validation.
| Organization | Application Area | Reported Metric / Output |
|---|---|---|
| Generate Biomedicines | CAR T-cell therapy | 70% shorter design; ~10x more receptors |
| Divergence Labs | Food allergy (IgE binding) | ~35,000 antibody designs; 20 dislodging hits |
| BigHat Biosciences | Lead optimization | 1,010 variants tested; >10x tighter binding |
| Enveda | Manufacturing paperwork | 89% reduction in manual review time (1,061 pages) |
Anthropic and Bristol Myers Squibb plan to expand their clinical trial evaluation framework through 2027.